Trial Profile
A Phase II Trial of Neoadjuvant Chemoradiation (CRT) and Pembrolizumab in Patients With Rectal Cancer: Hoosier Cancer Research Network GI15-213
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine
- Indications Rectal cancer
- Focus Therapeutic Use
- 05 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Aug 2016 Planned initiation date changed from 1 Mar 2016 to 1 Sep 2016.
- 04 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.